Now showing items 1-4 of 4
Comorbidity and its relevance on general hospital based mortality in major depressive disorder: A naturalistic 12-year follow-up in general hospital admissions
Major depressive disorder (MDD) is associated with physical comorbidity, but the risk factors of general hospital-based mortality are unclear. Consequently, we investigated whether the burden of comorbidity and its relevance ...
Sustained efficacy and safety of agomelatine versus placebo over 24 weeks in elderly out-patients suffering from major depressive disorder
With an increasingly ageing population, there is a growing need to develop novel ways to treat depression in the elderly. Few published placebo-controlled study results in elderly depressed patients reached a clinical ...
Efficacy of agomelatine in more anxious elderly depressed patients. A randomized, double-blind study vs placebo.
Agomelatine, has been shown to be effective and well-tolerated, in treating: major depressive disorder, anxiety symptoms of depression (1,2) and Generalized Anxiety Disorder (3,4). The present analysis evaluate the ...
The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: A placebo-controlled study
Objective: The present placebo-controlled study evaluated the efficacy, tolerability, and safety of 8-week treatment with agomelatine (25-50 mg/d by mouth) in elderly patients with major depressive disorder (MDD). Method: ...